FOXO1 Suppression Is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells through MET Upregulation
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells. Materials and Methods Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and reverse transcription–polymerase chain reaction were performed. Results SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin. Conclusion FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.
Abstract
Purpose Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells. Materials and Methods Lapatinib-resistant GC cell lines (SNU-216 LR2-8) were generated in vitro by chronic exposure of lapatinib-sensitive, HER2-positive SNU-216 cells to lapatinib. SNU-216 LR cells with FOXO1 overexpression were generated by stable transfection of a constitutively active FOXO1 mutant (FOXO1A3). HER2 and MET in SNU-216 LR cells were downregulated using RNA interference. The sensitivity of GC cells to lapatinib and/or cisplatin was determined by crystal violet assay. In addition, Western blot analysis, luciferase reporter assay and reverse transcription–polymerase chain reaction were performed. Results SNU-216 LR cells showed upregulations of HER2 and MET, but downregulation of FOXO1 compared to parental SNU-216 cells. FOXO1 overexpression in SNU-216 LR cells significantly suppressed resistance to lapatinib and/or cisplatin. In addition, FOXO1 negatively controlled HER2 and MET at the transcriptional level and was negatively controlled by these molecules at the post-transcriptional level. A positive crosstalk was shown between HER2 and MET, each of which increased resistance to lapatinib and/or cisplatin. Conclusion FOXO1 serves as an important linker between HER2 and MET signaling pathways through negative crosstalks and is a key regulator of the acquired lapatinib resistance in HER2-positive GC cells. These findings provide a rationale for establishing a novel treatment strategy to overcome lapatinib resistance in a subtype of GC patients.
참고문헌 (28)
- Gravalos C, "HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target", Ann Oncol, 19, pp.1523~1529 (2008)[DOI]
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)[DOI]
- Liu L, "Novel targeted agents for gastric cancer", J Hematol Oncol, 5, pp.31~ (2012)[DOI]
- Spector NL, "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies", J Clin Oncol, 23, pp.2502~2512 (2005)[DOI]
- Engelman JA, "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling", Science, 316, pp.1039~1043 (2007)[DOI]
- Corso S, "Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition", Mol Cancer, 9, pp.121~ (2010)[DOI]
- Lee HE, "MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome", Br J Cancer, 107, pp.325~333 (2012)[DOI]
- Nakajima M, "The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas", Cancer, 85, pp.1894~1902 (1999)[DOI]
- Ha SY, "HER2-positive gastric cancer with concomitant MET and", or EGFR overexpression: a distinct subset of patients for dual inhibition therapy, 2015, pp.136, 1629~1635
- Chen CT, "MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells", Mol Cancer Ther, 11, pp.660~669 (2012)[DOI]
- Zhang Z, "Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer", Clin Cancer Res, 20, pp.4559~4573 (2014)[DOI]
- Zhao M, "miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K", AKT-c-JUN, 2016, pp.7, 11309~
- Goto T, "The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers", Br J Cancer, 98, pp.1068~1075 (2008)[DOI]
- Han CY, "Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells", Carcinogenesis, 29, pp.1837~1844 (2008)[DOI]
- Park J, "The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase", Akt pathway, 2014, pp.17, 423~430
- Ko YS, "Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2", neu expression, 2015, pp.113, 1186~1196
- Kim HP, "Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer", Oncogene, 33, pp.3334~3341 (2014)[DOI]
- Kim WH, "Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin", Cancer Res, 54, pp.5005~5010 (1994)
- Kim JW, "The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines", Cancer Lett, 272, pp.296~306 (2008)[DOI]
- Satoh T, "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN: a randomized, phase III study", J Clin Oncol, 32, pp.2039~2049 (2014)[DOI]
- Sebolt-Leopold JS, "Mechanisms of drug inhibition of signalling molecules", Nature, 441, pp.457~462 (2006)[DOI]
- Sharma SV, "Oncogene addiction: setting the stage for molecularly targeted cancer therapy", Genes Dev, 21, pp.3214~3231 (2007)[DOI]
- Wu Y, "FOXO1A is a target for HER2-overexpressing breast tumors", Cancer Res, 70, pp.5475~5485 (2010)[DOI]
- Chakrabarty A, "Trastuzumab-resistant cells rely on a HER2-PI3KFoxO-survivin axis and are sensitive to PI3K inhibitors", Cancer Res, 73, pp.1190~1200 (2013)[DOI]
- Wang YC, "Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: role of estrogen receptor and HER2 reactivation", Breast Cancer Res, 13, pp.R121~ (2011)[DOI]
- Rusnak DW, "Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW57-2016) in an expanded panel of human normal and tumour cell lines", Cell Prolif, 40, pp.580~594 (2007)[DOI]
- Huang D, "Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition", Sci Rep, 6, pp.20502~ (2016)[DOI]
- Karamouzis MV, "Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors", Lancet Oncol, 10, pp.709~717 (2009)[DOI]